An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BeiGene to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
BeiGene, Ltd. (BGNE) will participate in fireside chats at two investor conferences, TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference. Live webcasts can be accessed on BeiGene's website, with archived replays available for 90 days.
Positive
None.
Negative
None.
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences:
TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:50 am ET; and
Leerink Partners Global Biopharma Conference on Monday, March 11th, 2024 at 10:00 am ET
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents, with administrative offices in Basel; Beijing; and Cambridge, U.S. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn and X (formerly known as Twitter) at @BeiGeneGlobal.
Forward-Looking Statements
This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law.
When will BeiGene participate in the fireside chats at the investor conferences?
BeiGene will participate in fireside chats at TD Cowen 44th Annual Health Care Conference on March 5th, 2024, and Leerink Partners Global Biopharma Conference on March 11th, 2024.
Where can I access the live webcasts of the investor conferences?
The live webcasts of the investor conferences can be accessed on BeiGene's website at http://ir.beigene.com, https://hkexir.beigene.com/, https://sseir.beigene.com/.
How long will the archived replays of the events be available?
Archived replays of the events will be available for 90 days following the conferences.
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.